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Les cellules sont la plus petite forme de vie individuelle qui forme un organisme. La structure et 
la santé de tous les organismes est essentiellement définie par le nombre, le type et la taille de 
leurs cellules. Composé d'environ 30 trillions de cellules, l'homme possède des cellules aux 
fonctions et aux tailles remarquablement variées, allant d'un neurone pouvant atteindre un mètre à 
une cellule lymphoïde d'environ 16 µm de diamètre. Il est connu que la taille est 
fondamentalement l'équilibre entre la croissance cellulaire et la division cellulaire. Néanmoins, 
les questions sur les réseaux moléculaires qui contrôlent et déterminent le maintien de la taille 
optimale des cellules restent à déchiffrer. D'innombrables travaux ont caractérisé mTORC1 
comme une voie régulatrice majeure de la croissance cellulaire jouant un rôle central, intégrant 
des stimuli intra et extracellulaires. Ce travail porte sur l'investigation et la caractérisation des 
acteurs moléculaires et des processus qui orchestrent la taille des cellules humaine déterminées 
par l'épistase chimique. J'ai entrepris une bibliothèque CRISPR / Cas9 à inactivation prolongée 
(EKO) dans NALM-6 (lignée cellulaire de lymphome pré-B), suivie d'un fractionnement de la 
taille des cellules par élutriation à contre-courant en présence de rapamycine (inhibiteur de 
mTOR), et comparé aux données non publiées données du laboratoire utilisant les mêmes 
méthodes sans rapamycine. Cette analyse de l'étude indique que dans le contexte amont de 
mTOR, la perte de gènes liés à la détection des nutriments entraîne une perte de taille en présence 
d'inhibition de mTOR. En outre, plusieurs knockouts géniques dans la biogenèse des ribosomes 
et l'homéostasie du calcium ont conduit à une perte ou un gain de taille, montrant un rôle pivot 
possible de ces processus dans le contrôle de la taille des cellules d'une manière dépendante de 
mTOR. Ce travail a fourni des informations sur les gènes et réseaux connus et inconnus qui 
peuvent réguler la taille des cellules d'une manière dépendante de mTOR. Ces résultats doivent 
être validés et approfondis. 
 
Mots-clés: taille des cellules, mTOR, CRISPR / Cas9, épistase, biogenèse des ribosomes, 





All organisms are essentially structured and fitness defined by cell number, type and size. 
Composed of around 30 trillion cells, humans have cells with remarkably varied functions and 
size, ranging from a neuron that can reach one meter in length to a lymphoid cell that is around 
16 µm in diameter. At a fundamental level, size is determined by the balance between cell growth 
and cell division. The molecular networks that control and maintain optimal cell size are yet to be 
deciphered. The mTORC1 pathway is a major regulator of cell growth that plays a central role in 
integrating intra- and extra-cellular stimuli. This study addresses the investigation and 
characterization of the molecular players and processes that orchestrate cell size in human cells, 
as determined by chemical-genetic size screens and epistasis analysis. I undertook a 
CRISPR/Cas9 extended-knockout (EKO) genome-wide library screen in the NALM-6 pre-B 
lymphoma cell line, followed by cell size fractionation by counter flow elutriation in the presence 
of the mTOR inhibitor rapamycin, and compared the screen data to a similar screen performed in 
the absence of rapamycin. The analysis indicates that upstream of mTOR, the loss of genes that 
are related to nutrient sensing, results in size changes in the presence of mTOR inhibition. Also, 
several gene knockouts in ribosome biogenesis and calcium homeostasis led to size alterations, 
suggesting a possible a pivotal role of these processes in cell size control in a mTOR-dependent 
fashion. This study provides insights into the genetic networks that regulate cell size in a mTOR-
dependent fashion and establishes new hypotheses for future experimental tests. 
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1.1 The enormous variation of cell and organism size in nature  
 
Among the ∼8.74 million species of existing eukaryotes on Earth (Mora et al. 2011), from fungi 
to mammals, size heterogeneity is amongst the most prominent features. Size and shape at the 
cell, tissue and organism level are characteristic for each species, and can often vary in 
accordance with  environmental conditions (Vollmer, Casares, & Iber, 2017). 
 
In 1926, Haldane stated “The most obvious differences between different animals are differences 
of size, but for some reason the zoologists have paid singularly little attention to them”, and in 
the same work concluded: “For every type of animal there is a most convenient size, and a large 
change in size inevitably carries with it a change of form” (Haldane, 1926). 
 
Andersen et al. (2015) stated how despite obvious differences in all organisms “biologists have 
used organism size as a master trait to characterize the capabilities and limitations of individual 
organisms” (Andersen et al., 2015). Size has been used as a parameter to study a diverse range 
of traits in biology such as in predator and prey relationships (Hansen, Bjørnsen, & Hansen, 
1997; Rall et al., 2012), fluid mechanical forces (Bejan, Marden, & Ansell, 2006), and 
metabolism (West, Brown, & Enquist, 1997). Moreover, differences in animal size have been 
shaped by evolution and has direct consequences on organism fitness (West et al., 1997).  
 
Animal development usually occurs in sequence from a smaller version of the individual 
organism followed by growth to the optimal size, as accomplished by cell growth and/or division 
(Conlon & Raff, 1999). Similarly, in metazoans different types of cells have different sizes and 
shapes that are attuned to specific functions. The heterogeneity in cell sizes is enormous, for 
example in humans a neutrophil is approximately 10 um in diameter while an adult neuron can 
be one meter in length (Figure 1) (Guertin & Sabatini, 2006). These observations underscore the 





Figure 1: Cell size heterogeneity in nature. 
 
Schematic representation of cell size variation within and between species. Single celled budding 
and fission yeast have an average size of 3µm, whereas in mammals hepatocytes are on average 
20-30µm in diameter, oocytes are 100 µm in diameter, and neuron can be up to 1 meter-long. 
Taken from Guertin and Sabatini (2006). 
 
1.2 The concepts of size, growth and division 
 
In the present study, cell growth in dividing cells will be discussed. Accompanied by 
proliferation, cell size across successive generations is remarkably constant and characteristic of 




The terms cell size, growth, division and proliferation are often confused. Here, the term cell size 
is used to refer to the volume of a cell at the time of the measurement, typically measured by 
electrolyte displacement with a Coulter multisizer, which will usually correlate with cell mass. 
Cell growth is used to describe the process of mass accumulation due to macromolecular 
biosynthesis. This process leads to an increase in size or volume. For this reason, the term cell 
growth if often used to refer to the process of volume and size accumulation that results from an 
increase of mass (Guertin & Sabatini, 2006; Lloyd, 2013). Cell proliferation or cell division 
refers to duplication and segregation of the genome and other cellular components that generates 
two daughter cells from a precursor mother cell. (Salazar-Roa & Malumbres, 2016). Cell growth 
and cell division can be separable processes (Jorgensen & Tyers, 2002). An example of this is 
that cells can grow without division (e.g., a postmitotic neuron) and divide without growing (e.g., 
a fertilized egg) (Lloyd, 2013; Su & O’Farrell, 1998). However, typically cells grow in each 
division cycle to maintain the size of daughter cells close to that of the mother cell (Guertin & 
Sabatini, 2006). Each cell is thus thought to attain a minimal size in order to progress through the 
cell cycle (Su & O’Farrell, 1998), termed the size threshold. As above, the size threshold is 
dictated by cell type and differentiation state. 
 
Cells appear to have an optimal size that maintains a specific volume to area ratio. For example, 
if cells become too large intracellular transport becomes inefficient, so large organisms are 
composed of more cells not bigger cells (Guertin, 2006). Cell size is also highly correlated with 
ploidy, such that increased ploidy leads to proportionately bigger cells (Jorgensen & Tyers 2002; 
Guertin, 2006). For example, during the development of a megakaryoblast (about 20–30 mm in 
diameter) into a granular megakaryocytes (±100 mm in diameter), cells do not divide but instead 
undergo multiple rounds of DNA replication (Guertin, 2006). Another example in an organism-
specific context is the salamander, in which tetraploid animals are the same size as diploid 
animals but are composed of half as many cells of twice the size (Conlon & Raff, 1999; 
Fankhauser, 1952). 
 
Nutritional status also regulates cell size. When under unfavorable nutrition conditions cells tend 
to be smaller from unicellular to multi-cellular organisms (Davie & Petersen, 2012; Fantes & 
Nurse, 1977; Kim et al., 2002). For example, yeast cells grown in a rich carbon source such as 
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glucose are larger than cells grown in a poor carbon source such as ethanol or glycerol. 
Interestingly, this nutritional dependency may operate at the organism level including for 
humans as observed in the reduced growth of children born during wartime (Hermanussen, 
Bogin, & Scheffler, 2018). 
 
The deregulation of cell size is often linked to disease, and many examples can be cited. 
Tuberous sclerosis (TSC) and angioleiomyomatosis (LAM), which cause the development of 
benign tumors in the brain, kidney, lungs, and skin are due to mutations in TSC1 or TSC2, 
leading to hyper-growth signaling (Guertin, 2006). Peutz–Jeghers syndrome is another disease 
related to mutations in the growth-regulator gene, LKB1, leading to benign tumors in the 
stomach, intestine, and skin (Guertin, 2006). Fetal macrosomia describes the oversize of a 
newborn, which occurs in 15-45% of diabetic mothers. These newborns tend to develop 
hypertrophic cardiomyopathy, obesity, diabetes, and this condition is believed to be result of the 
maternal hyperglycemia leading to fetal hyperglycemia (Araujo et al., 2017; Kamana et al., 
2015; Mormile, 2016).  
 
In the cancer context, the loss of control over size, growth and division is virtually universal and 
represents on the hallmarks of cancer (Hanahan & Weinberg, 2011). The ability to maintain 
chronic proliferation, either by activating mutations, disrupting negative feedbacks or by the 
excess of proliferative signaling thus leads to the ablation of size, growth and tissue architecture 
homeostasis (Hanahan & Weinberg, 2011). 
 
1.3 Size homeostasis results from the balance between cell growth and cell 
division 
 
Cell growth and cell division are fundamental to organismal growth (Conlon & Raff, 2003), and 
the cell cycle is a primary process that effects coordination of growth and proliferation. In 
proliferating cells this coordination can occur through both the dependency of division on growth 
and growth on division (Jorgensen & Tyers, 2002). The cell cycle is an all-or-nothing process 
that progresses in an unidirectional manner and depends on a host of mitogenic factors in 
multicellular organisms, including humans. Unlike microorganisms, metazoans require growth 
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factor signaling and may arrest or undergo autophagy despite abundant extracellular nutrients 
(Lloyd, 2013; Lum et al., 2005; Conlon & Raff, 1999). Although the signaling processes that 
trigger division have been described in great detail, precisely how cells coordinate cell growth 
and cell cycle progression to maintain an equilibrium or homeostatic size is not known. 
 
Cells must achieve a minimum size in order to commit to cell division. Many observations 
demonstrate that a cell size threshold in late G1 phase gates entry into the division cycle. In 
1926, Hartman (Hartmann, 1926)
 
published the first results indicating that cells need to achieve a 
specific size to divide. In Amoeba proteus¸ he periodically amputated part of the amoeba’s 
cytoplasm for more than 150 days. This experiment blocked cell division during the entire period 
of the experiment, during which time control cells divided 65 times. Some years later, the same 
experiment was reproduced and similar results were found (Prescott, 1956). In E.coli, cells 
displayed a uniformly consistent size at the initiation of DNA synthesis (Donachie, 1968), 
suggesting that bacteria also need to achieve a minimum size before division. 
 
1.4 Cell size threshold in yeast 
 
In the early 1970s experiments in the fission yeast Schizosaccharomyces pombe (S. pombe) and 
the budding yeast Sacharromyces cerevisiae provided the first genetic evidence for cell size 
control (Hartwell, Culotti, & Reid, 1970; Hartwell et al., 1973; Nurse, 1975). Through 
identification of mutations that led to the arrest of the cell cycle in different phases, many cell 
division control genes (abbreviated cdc in S. pombe and CDC in S. cerevisiae) opened the field 
to the study of the relationship between cell growth and cell division. It was immediately obvious 
that mutant cells with a defective cell cycle kept growing, reaching volumes of two to three-fold 
of the control volume. Whereas, cells in low nutrient conditions or with mutations in nutrient 
signalling processes displayed cell cycle arrest in G1 (Hartwell et al., 1970; Hartwell et al., 1973; 
Johnston, Pringle, & Hartwell, 1977). This was the first time that the term critical cell size was 
used, meaning that cells need to achieve a minimum volume to proceed in the cell cycle, i.e., the 
first indication of a cell size threshold. In this context, the concept of “Start” arose defining the 
moment when yeast commits to the cell division, after acquiring the critical size at the end of G1 
(Johnston et al., 1977). This study led to the view that growth and division are separate but 
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coupled processes since cells can grow without dividing. More recent studies showed that the 
cell cycle exerts reciprocal control on cell growth. For example, Goranov et al. (2009) found that 
growth rates change during different phases of the cell cycle, being the highest during anaphase 
and G1. 
 
In yeast, the interplay between environmental conditions and size were first demonstrated to 
influence size homeostasis. The investigation of cell size and proliferation of S. pombe under 
different experimental conditions showed that both temperature and nutritional deprivation 
affected the size. Poor nitrogen, carbon or phosphate availability resulted in decreased growth 
rates, size, and proliferation (Fantes & Nurse, 1977). Based on the results obtained in their 
investigation on cell size upon environmental conditions, Fantes & Nurse (1977), stated that 
“The cell size necessary for the nuclear division is set, or modulated, by the prevailing growth 
conditions”. 
 
In the same year, Fantes & Nurse (1977) used temperature sensitive mutants to evaluate the 
relationship between cell size and cell cycle time in S. pombe. A cdc mutant strain that grew 
normally at 25°C but arrested in nuclear division at 35°C was used to generate abnormally large 
cells that exceeded the size threshold and entered division rapidly upon return to 25°C (Fantes & 
Nurse, 1977). Taken together, these results and many other experiments consolidated the concept 
that a commitment point at the end of G1 phase gates irreversible entrance into the cell cycle and 
that passage through this point depends on growth to a minimal cell size. 
 
1.5 Cell size threshold in animals 
 
The discussion about a cell size threshold in mammalian cells started in the mid-'60s. In classic 
studies published in 1965, Killander & Zetterberg (1965a; 1965b) provided the first clear 
evidence that “cells which had just started their DNA synthesis showed less mass variation than 
cells in initial phases of interphase, indicating the relationship between cell mass and the 




In the first such study in mouse fibroblasts, it was shown that DNA synthesis is initiated only 
upon attaining a critical size or mass and that small new daughter cells require more time to 
achieve this critical mass whereas bigger cells requires less time (Killander & Zetterberg, 
1965a). In further study on mouse fibroblasts populations, smaller cells correspondingly spent a 
longer period in G1 than bigger cells, corroborating the idea that initiation of DNA synthesis 
depends on a minimal cell mass (Killander & Zetterberg, 1965b). 
 
After this pioneering research many groups started to investigate the cell size threshold in 
mammalian cells in different conditions and different models. G1 phase displayed a longer 
duration in small daughter when in comparison with bigger mother cells, resulting in an unequal 
division in Chinese hamster cells, rat oligodendrocytes precursor cells, and mouse embryonic 
fibroblasts (Gao & Raff, 1997; Kimball et al., 1971; Shields et al., 1978). These studies helped to 
buttress the idea that like single-celled eukaryotes the mammalian system also has a size 
threshold (Figure 1.2). Serum starvation and amino acid deprivation also caused cells to fail to 
proliferate and became quiescent. This quiescent state was reversed upon the restoration of 
optimal nutritional conditions (Pardee, 1974). This study led to the idea that mammalian cells 
have a “restriction point”, analogous to start in yeast, in which commitment to division depends 
on growth to a minimal size (Figure 1.2). 
 
Conlon and Raff (2003), argued in rat Schwann cells a cell size threshold may not be needed to 
maintain the size distribution. Schwann cells appear to grow at the same rate independent of their 
initial size suggesting that cells may converge to a uniform size by the simple fact that smaller 
cells grow proportionately faster than large cells (Conlon & Raff, 2003). However, this effect 
may be cell type specific as considerable more recent data strongly argues that a size threshold 
does operate in mammalian cells, as discussed extensively in Ginzberg et al. (2018). As in yeast,  
the mammalian cell cycle also appears to exert control over cell growth in certain contexts 











Figure 2: Critical cell size threshold 
Scheme representing cells in different distributions of size in G1 growing until achieving the 
minimal sufficient size to pass the cell size threshold (vertical bars), entry in S phase and commit 
definitely to the cell cycle. Adapted from Ginzberg, Kafri, & Kirschner (2015). 
 
1.6 Cell size screens in yeast 
 
Whole-genome systematic screens in S. cerevisiae allowed the identification of essential genes 
and genes that resulted in growth defects (Winzeler et al., 1999) and started a new era of systems 
genetics. Application of these genome-scale reagent collections to the problem of cell size 
identified hundreds of new genes that directly or indirectly regulate cell size and the cellular 
processes involved in this regulation (Jorgensen et al., 2002; Jorgensen et al., 2004). In 2002, 
Tyers Lab published the first global gene deletion of around 6000 strains, analysing the effect of 
gene loss on cell size using cultures in exponential growth, identifying that 10% of gene 
deletions result in a size phenotype (Jorgensen et al., 2002). This study tested the effect of 
diploid mutations in essential genes, finding an increase in size in up to ∼40% (large or lge) of 
the strains, and an opposite effect in ∼15% (small or whi), when compared with the median cell 
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size. As a conclusion, it was discussed that larger haploinsufficient cells are often defective in 
components of the 26S proteasome, γ-tubulin complex and ribosome biogenesis; while whi 
mutants often are involved in ribosome biogenesis, nucleolar function and ribosomal subunits. 
Further on, ∼500 strains with haploid deletions and sizes distinct from wild-type cells, required 
more tests in order to define genes that directs cell size at Start. Finally a synthetic genetic array 
was performed (i.e. synthetic lethal interactions with known regulators of Start), and between 
several whi mutants WHI5, CDH1, and SFP1 were negative regulators of Start (Jorgensen et al., 
2002). In 2002, Zhang et al. (2002) performed a similar analysis on stationary phase cells and 
recovered many of the same genes. 
 
Among the many genes identified in these studies, a number appeared to be central regulators of 
growth and division including Sfp1, Sch9, Cdh1, Prs3, and Whi5. Sfp1 and Sch9 are both 
involved in ribosomal biogenesis and serve to activate the ribosomal protein (RP) and ribosome 
biogenesis (Ribi) regulons downstream pathway of the TOR (Target of Rapamycin) signaling 
network. TOR is highly conserved from yeast to mammals, and in yeast it controls the interplay 
between nutritional and translational status and ribosomal production via Sfp1 and Sch9 
(Gonzalez & Rallis, 2017; Lempiäinen et al., 2009; Loewith et al., 2002; Singh & Tyers, 2009; 
Urban et al., 2007). 
 
1.7 The mechanistic target of rapamycin 
 
Studies in yeast, flies, mice and human cells revealed the conserved target of rapamycin (TOR) 
pathway to be a crucial regulator of cell growth and cell size. In metazoan cells, this pathway is 
now referred to as the mechanistic target of rapamycin or mTOR pathway. 
 
The PI3K/AKT/mTORC1 pathway is evolutionarily conserved and shown to be a crucial 
regulator of cell growth and size (Lloyd, 2013). In mammals there is one TOR gene that encodes 
for the catalytic subunit of two complexes: mTORC1 and mTORC2 (Jefferies et al., 1997; 
Wullschleger, Loewith, & Hall, 2006b; Saxton & Sabatini, 2017). mTOR is a serine/threonine 
protein kinase, which forms two distinct mTOR complexes differs from its molecular 
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components, sensitivity to its inhibitor rapamycin, downstream targets, and cellular responses 
(Figure 3) (Morita et al., 2015; Saxton & Sabatini, 2017). 
 
Figure 3: mTORC1 and mTORC2 complexes: Composition, extracellular interactors, and 
cellular responses. 
The central mTOR kinase forms two distinct complexes: mTORC1 and mTORC2. mTORC1 
senses cellular levels of amino acids, stress, energy levels, growth factors, and is sensitive to 
rapamycin. In response to this stimulus it orchestrates growth, cell cycle, autophagy, 
macromolecule biogenesis and metabolism. Differently, mTORC2 respond to growth factors, 
regulating the cytoskeletal organization and cell survival. Despite having the same central mTOR 
kinase, the complexes are composed of different proteins. Taken from Showkat, Beigh, & 
Andrabi (2014a). 
 
The mTOR complex 1 promotes anabolic metabolism: ribosome biogenesis, lipid synthesis, 
mRNA translation. Because of its role in the metabolism mTORC1 is a central player of cellular 
systems being a sensor of nutrients, growth factors, stress, oxygen and energy levels of the cell 
(Wullschleger et al., 2006b; Sengupta, Peterson, & Sabatini, 2010; Loewith et al., 2002). These 
topics will be discussed in the next section. 
 
TOR was first discovered due to the identification of a compound with antimicrobial, 
immunosuppressive, and antitumor properties, later named rapamycin due to its isolation in the 
South Pacific island of Rapa Nui in 1964 (Saxton & Sabatini, 2017). Budding yeast cells treated 
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with rapamycin displayed a similar phenotype as cells depleted for the TOR1/2 genes, i.e., an 
arrest in G1 (Barbet et al., 1996). Absence of TOR function caused translation inhibition and 
characteristics of cells entering in GO caused by starvation. This study suggested TOR is a 
crucial sensor of nutritional status and is required for growth and consequent cell cycle 
commitment (Barbet et al., 1996). Subsequent work investigating TOR in different models 
revealed a plethora of functions. From yeast to humans TOR has conserved in the regulation of 
growth, and it was probably one of the biggest milestones in the understanding of eukaryotic 
regulation of size, proliferation and cell cycle progression (De Virgilio & Loewith, 2006; 
Loewith et al., 2002; Wullschleger et al., 2006b). 
 
The core components of mTORC1 are mTOR, Raptor, and mLST8. Raptor acts to recruit 
substrate to the complex and confers correct subcellular localization whereas mLST8 interacts 
with the mTORC1 catalytic domain and promotes kinase activation (Guertin et al., 2006; Saxton 
& Sabatini, 2017). mTORC1 is sensitive to acute rapamycin treatment, whereby a complex of 
rapamycin-FKBP12 (FK506-binding protein of 12 kDa) binds and inhibits mTORC1 (Chiu, 
Katz, & Berlint, 1994; Saxton & Sabatini, 2017; Roux & Topisirovic, 2012). 
 
Downstream targets of mTOR mediate the cellular responses initiated by both TORC complexes.  
mTORC1 plays a central role in anabolic processes by regulating the rates of protein synthesis 
and turnover, as well as lipid, nucleotide and glucose metabolism (Morita et al., 2015; Saxton & 
Sabatini, 2017). Protein synthesis is mainly mediated by mTORC1 through the phosphorylation 
of S6K1 and 4EBPs. The direct phosphorylation of S6K1 by mTORC1 promotes mRNA 
translation initiation by the activation of several substrates. 4EBP is another branch of mTORC1 
protein synthesis, in which 4EBP is phosphorylated by mTORC1 causing its dissociation from 
eIF4E, thus enabling mRNA translation (Saxton & Sabatini, 2017). 
 
The metabolism of lipids, nucleotides, and glucose is especially important for membrane 
formation and maintenance. This metabolism is mediated by transcription factors. In this study 
SREBP (sterol responsive element binding protein) was found to be controlling the expression of 
genes that regulate both fatty acids and cholesterol biosynthesis (Brown & Goldstein, 1997; 
Saxton & Sabatini, 2017). Since mTORC1 acts as a sensor of sterol levels, and upon its low 
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levels initiates a cascade of SREBP activation through S6K1, this might be the interface between  
SREBP  and mTORC1 (Porstmann et al., 2008; Saxton & Sabatini, 2017). 
 
The synthesis of nucleotides necessary for DNA and ribosome biogenesis is crucial for cell 
proliferation. In this context mTORC1 is related to those events by two branches: the expression 
of MTHFD2, that is involved in de novo purine synthesis by the regulation of the mitochondrial 
tetrahydrofolate cycle and, by S6K1 phosphorylation of CAD (carbamoyl-phosphate synthetase), 
regulating pyrimidine synthesis (Ben-Sahra et al., 2016; Saxton & Sabatini, 2017; Trajkovska, 
2013). 
 
The regulation of proliferation is also facilitated by mTORC1 through the control of oxidative 
phosphorylation versus glycolysis promoting the transformation of nutrients in biomass. HIF1α 
controls the expression of glycolytic enzymes, which in turn has its expression regulated by 
mTORC1. Also, the activation of SREBP (sterol regulatory element-binding protein) promotes 
proliferation mediated by S6K1, promoting an increase in the flux through the oxidative pentose 
phosphate pathway (PPP) leading to a change in the energetic metabolism to generate NADPH 
(Düvel et al., 2010; Saxton & Sabatini, 2017). 
 
Besides the enhancement of cell anabolic processes, mTORC1 stimulates cell growth through the 
suppression of catabolism in particular autophagy. Under favorable nutritional status mTORC1 
prevents the activation of ULK1, an important autophagosome driver (Saxton and Sabatini 
2017). Another means by which mTORC1 regulates protein turnover is by the regulation of 
protein ubiquitylation and proteasome-dependent degradation (Saxton & Sabatini, 2017). 
 
1.8 Downstream effectors of mTORC1 
 
Protein translation is a complex process composed of many steps and different molecules. In this 
context mTORC1 controls many cellular functions. One in particular being ribosome recruitment 
to mRNA by activating two major players in the translational machinery: eukaryotic translation 
initiation factor 4E (4E-BPs) and the ribosomal S6 kinase proteins (S6Ks) (Nissim Hay & 




One of the crucial points of eukaryotic translation regulation is ribosome recruitment to the 5’ 
mRNA end in the start codon (Gingras, Raught, & Sonenberg, 1999). These structures possess a 
cap recognition region (m7GpppN, “m” representing a methyl group and “N”, any nucleotide) 
that has many functions, including pre-mRNA processing, mRNA stability and its export and 
translation (Showkat, Beigh, & Andrabi, 2014b). Translation initiation factors facilitate ribosome 
binding to the mRNA 5’ end, where eIF4E binds specifically promoting cap-dependent 
translation initiation mediated by eIF4E binding proteins (4E-BPs) phosphorylation 
(Wullschleger et al., 2006a).  
 
The translation is then followed by the unwinding of the molecule that is mediated by eIF4E 
(Hay & Sonenberg, 2004). Several proteins involved in the process of ribosomal recruitment 
machinery are directly or indirectly targeted by mTOR either by phosphorylated or sequestration 
by 4E-BPs (Hay & Sonenberg, 2004; Showkat et al., 2014b). 4E-BP1 is phosphorylated by 
mTORC1 in several residues, promoting the inhibition of eIF4E dependent translation initiation 
and consequently of protein translation inhibition (Showkat et al., 2014b).  
 
S6K1 is the most well-characterized mTORC1 target. The S6K family is composed of two genes, 
S2K1 and S6K2 that share 70% homology. It is a serine/threonine kinase composed of five 
domains, and when phosphorylated in its serine/threonine region opens the kinase domain 
releasing its autoinhibition (Tavares et al., 2015; Showkat et al., 2014b). This family has a 
pronounced role in the control of cell growth and cell size. In mice knockout of those proteins 
have opposite outcomes: while S6K2 knockout leads to increased size, S6K1 generates animals 
smaller than controls (Shima et al., 1998) and the double S6K knockouts lead to perinatal 
mortality (Pende et al., 2004; Shima et al., 1998). 
 
The S6K family interacts with a plethora of proteins, regulating many different cellular 
outcomes: metabolism, apoptosis, cell proliferation, signal transduction, cytoskeleton 
organization, inflammation, protein synthesis, mRNA, transcription, splicing, transcription and 




1.9 mTORC1 and cancer 
 
Due to its broad impact in the maintenance of cell homeostasis, aberrant activation of mTOR 
pathway is involved in many diseases including cancer. Both activation of oncogenes or loss of 
tumor suppression upstream and downstream mTOR are found in many cancers and directly 
impact cell growth, metabolism and proliferation (Showkat et al., 2014b; Wullschleger et al., 
2006b). 
 
Upstream mTOR alterations are common. Growth factor receptor overexpression such as IGFR 
(insulin-like growth factor receptor) and HER2 (human epidermal growth factor receptor 2), can 
lead to activation of mTOR pathway (Showkat et al., 2014b). Several PI3K pathway components 
are mutated in human cancers including amplification of genes encoding the catalytic subunits of 
PI3K and AKT, activation of the Ras small GTPase and mutation of the PTEN lipid phosphatase 
(Laplante & Sabatini, 2012; Hay & Sonenberg, 2004; Simpson & Parsons, 2001). Oncogenic 
activation of the networks upstream of mTOR triggers cell growth, proliferation and survival 
(Laplante & Sabatini, 2012). Related alterations in more direct interactors of mTOR like 
mutations in TSC1 and TSC2 causing hamartomas and a frequent amplification in Rheb locus 
involved in development and poor prognosis of many epithelial and squamous cancers further 
underscore the key role of the mTOR pathway in cancer (Armijo et al., 2016; Hay & Sonenberg, 
2004). 
 
Growing evidence suggests that the machinery downstream mTOR leads to unbalanced proteins 
synthesis and plays a central role in the cancer genesis. 4EBP1/eIF4E is involved in tumor 
formation as upon its loss 4EBP1/2 causes activation of cap-dependent translation promoting 
cell-cycle progression and proliferation (Dowling et al., 2010). Both 4EBP1 and eIF4E are 
critical players in the PI3K-Akt-mTOR oncogenic activity. Hsieh et al. (2010) showed the 
hyperactivation of 4EBP-eIF4E axis increasing tumor growth, and the phosphorylation of 4EBP1 
being required for the increase of protein synthesis and cell size control downstream of AKT 
signaling. Lynch et al. (2004) discussed that eIF4E is a cell cycle and cell size rate-limiting 
component, that controls G1 by translation initiation factors orchestration. Also in the mTORT 
and cancer context, S6K1 is an important arm downstream in the pathway, and its role in 
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oncogenesis is still debated. S6K1 was found overexpressed in ovary cancer and its gene 
expression is upregulated in brain tumors (Bärlund et al., 2000; Ismail, 2012). However, its 
contribution to the oncogenic action of ERK and/or Akt is debated (Hsieh et al., 2010; She et al., 
2010). 
 
1.10 Systematic mammalian cell size screens and CRISPR/Cas9 genome-editing 
technology 
 
Previous studies in budding yeast revealed hundreds of genes that regulate size. Those results 
were possible due to large-scale technologies which made possible the generation of a genome-
wide deletion collection, and the use of this collection in numerous genetic screens (Dungrawala 
et al., 2012; Jorgensen et al., 2002; Zhang et al., 2002). Many gene functions revealed by these 
screens are conserved such as the mTOR network (Virgilio & Loewith, 2006; Jorgensen & 
Tyers, 2002). These findings motivated the application of large-scale approaches to screen the 
genes that regulate cell growth and cell division in mammalian cells.  In the early 2000s studies 
using small interfering RNA (siRNA) or short hairpin RNA (shRNA) libraries yielded new 
insights into cancer and other processes but high rates of off-target effects compromised the 
interpretation of screen hits (Echeverri et al., 2006). The advent of technology based on the 
clustered regularly interspaced short palindromic repeats (CRISPR) targeted endonuclease 
system of bacteria has enabled high fidelity genome-scale screens that have revolutionized 
functional genomics in mammalian cells. 
 
CRISPR/Cas9 technology is based on the immune system of bacteria and archaea against the 
invading virus. The resistance is founded on the incorporation of short DNA sequences of the 
invader in genomic CRISPR loci that functions as a genetic memory, such that upon the 
recognition of the foreign sequence the host can destroy the sequence using cas9 CRISPR-
associated genes (Brouns et al., 2008). 
 
Between the different CRISPR forms, most well characterized is from Streptococcus pyogenes. 
CRISPR/Cas9 functions as a molecular scissor that identifies its target DNA sequence using an 
RNA-guided double-stranded DNA nuclease (Garneau et al., 2010; Jiang & Doudna, 2017). The 
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enzyme Cas9 (S. pyogenes) direct its double strand cut using a short 20 nucleotide sequence of 
DNA associated with a guide RNA (Figure 4) (Jiang & Doudna, 2017). 
 
 
Figure 4: The CRISPR/Cas9 function 
The CRISPR/Cas9 system is based on the targeting of specific DNA sequences, directed by a 20 
nucleotide sgRNA (blue) generating a double strand break created by the Cas9 enzyme 3 base 
pairs upstream of the PAM motif. Taken from Ran et al. (2013). 
 
Initially, the system was designed to contain a tracrRNA (trans-activating CRISPR RNA), host 
factor ribonuclease (RNase) III, and Cas9 nuclease (Brouns et al., 2008). Improvements in the 
technology were made generating a single sgRNA fusion containing all the previous 
components, and the addition of the Protospacer Adjacent Motif (PAM) flanking its 3’ end of the 
DNA target sequence (Figure 4). The Cas9 scans the DNA, allowing the sgRNA to pair with 
complementary sequence and Cas9 to cut the sequence in average 3 or 4 nucleotides upstream 
the PAM sequence (Brouns et al., 2008). 
 
The DNA breaks generated by the Cas9 activate repair mechanisms. Based on the kind of break 
that the Cas9 induces in the DNA the most common repair mechanism activated is the NHEJ 
(non-homologous end joining). This mechanism is error-prone, it causes deletions and insertions 
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(indels) at the break site. This often causes changes in the frameshift read, and consequent 
protein inactivation (Cong et al., 2013; Ran et al., 2013). 
 
The CRISPR/Cas9 system quickly became an easy, cost-effective precise and versatile tool for 
gene editing that was rapidly adapted into interrogate gene function on a genome-wide scale in 
mammalian cells. A GeCKO (Genome-scale CRISPR/Cas9 KO) library of pooled sgRNAs 
targeting around 18,000 RefSeq genes was generated with a coverage of 3 sgRNAs per gene 
(Shalem et al., 2014). In the same year, a smaller library was generated, targeting approximately 
7000 genes with a coverage of 10 sgRNAs per gene and the addition of 100 non-targeting 
sgRNAs as controls (Wang et al., 2014). Those studies helped to build the large-scale design of 
pooled libraries using CRISPR/Cas9 technology in mammalian cells. In a previous study, Tyers 
group created a genome-wide extended knockout (EKO) library (Bertomeu et al., 2017). The 
EKO library contains 278,754 sgRNAs that targets 19,084 RefSeq annotated genes, and an 
extended fraction of the library including 20,852 sgRNAs targeting alternative exons and 3,872 
hypothetical genes. In order to interrogate the molecular pathways that regulate cell size in 
humans, I used this library and performed a large-scale knockout screen in a chemical epistasis 






2.1. Culture density effects on cell size and cell cycle distribution  
 
Finding the optimal conditions for cell culture is critical for reproducibility and accuracy. In this 
study the aim was to evaluate cell size therefore, validating that this variable was not affected by 
culture conditions was crucial to ensure the quality of the analysis. As discussed before growth 
and division are coupled phenomena, and for this reason the impact of cell density and division 
over size was evaluated. Initially, NALM-6 growth rates and size were characterized. Cells were 
seeded at different concentrations and followed for 4 days without further dilutions. Those 
samples were red on the Z2 Coulter to asses size and concentration and were evaluated in the 
coulter daily. NALM-6 is a pre-B acute lymphoblastic leukemia cell. This cell grows in 
suspension and has a doubling time of 25 hours, those characteristics allows a reproduction at the 
cell counting time and suspension cells are ideal to perform the elutriation. Also, NALM-6 is 
widely used in studies evaluating mTOR, and has expression of all key components of 
































Figure 5: Cell size depends on culture density. 
Asynchronous cells were seeded in different concentrations followed by the measurement of size 
and density during a 4 day period. Initial cell density was A) 1000 000 cells per mL. B) 120 000 
cells per mL. C) 140 000 cells per mL. D) 160 000 cells per mL. E) 180 000 cells per mL. F) 200 
000 cells per mL. The dashed lines represent the cell size in the major concentration of cells in 
the fourth day, showing a smaller cell size phenotype in all concentrations starting from 160 000 
cells per mL (D). 
 
Regarding cell size it was observed that cell density leads to smaller cells when comparing 
different days in the same experiment (figure 5 A-F). This observation was even more dramatic 
when comparing experiments from lower initial density (figure 5 A) with those with higher cell 
density (figure 5 F) 
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Seeded at 120 000 cells/mL 
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When analysing the proliferation rates of the above-mentioned experiment it was observed that 
the lower concentrations (100 000, 120 000 and 140 000 cells per mL) start to reach the 
proliferation plateau at day 3, while the most concentrated samples reach the same levels at day 









Figure 6: Cell proliferation achieves saturation in similar coulter density. 
Nalm-6 cells seeded in different concentrations were quantified daily. Cells from different initial 
concentrations achieved saturation in similar culture density in all evaluated concentrations. 
 
The same experiment was also analysed for changes in the cell cycle. Cells were ethanol-fixed, 
and cell cycle distribution was assessed by FACS based analysis of DNA content (Figure 7). 
The dashed lines indicate at what day the cell cycle pattern started to change. At a 100 000 cells 
per mL the cell cycle started to change at day 4 (Figure 7 A), the other experiments started 
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Figure 7: Cell cycle distribution changes according to coulter density. 
Cell cycle distribution for all the seeded concentrations was evaluated using FACS/PI. The 
dashed lines represent changes in the cell cycle distribution compared to previous days. Cell 
cycle distribution for the less concentrated dilution (A) started to change at day 4, further on all 
dilutions displayed different cell cycle distribution from day 3 (B-F). In the most concentrated 
dilations (D-F) it’s possible to see an increase in G1 distribution on day 4, being the G1 



























































































































































The variation in cell cycle distribution appears to be related to cell density. In all cases, the first 
modification in the cell cycle was a maintenance S phase, increase in S, and decrease in G2 
phase (Figure 7 B-F). The increase in cell density showed a change in this pattern: in the 
samples seeded at 120 000 cells per mL (Figure 7 B), day 4 displayed a similar distribution as 
observed in day 3 tending to increase in S phase and decrease in G2. In all the experiments with 
higher initial concentrations starting from 140 000 cells per mL (Figure 7 C) presented an 
increase in G1 arrest and at day 4 when compared with day 3 (Figure 7 C-E). 
 
Initially, it was observed that up to 100 000 cells per mL the cell size distribution does not 
change in any of the observed days (Figure 5 A, B, and C). Cells started to display a reduction 
in cell size in the later initial cell density (Figure 5 D, E, and F) in all the observed days with a 
dramatic reduction in size in the last observed day from the initial concentration of 200 000, i.e., 
the most concentrated culture density used (Figure 5 F). Those results can be correlated to the 
ones in the cell cycle distribution where the changes in cell cycle distribution appear to happen 
before the change in size (Figure 7 A, B, C, D, E, and F). With attention to day 4 of the 200 000 
experiment the only observed experiment with a strong G1 arrest (Figure 7 F), was also the one 
that reached the smallest cell size. 
 
Finally, as observed in Figure 6, the exponential phase of the cells in all the seeded initial 
concentrations started in 400 000
 
per ml and all the concentrations achieved a proliferation 
plateau at an overall of 1600 000 cell per mL. This result helped to set the optimal work 
concentration for further analysis. Since this study aimed to analyze the genetic regulators of 
size, cells needed to be kept in the exponential proliferation phase to avoid cell synchronization 
and unwanted bias.  
 
The analysis does not differentiate between cells in early G1 and late G1, and heterogeneity of 
the G1 distribution might be masking the effect of loss in size inside of the analysed cell cycle 
phases. Nevertheless, on day 4 at the densest concentrations the effect of higher G1 distributions 
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(Figure 7 D, E and F), can be seen in the analysis of size (Figure 5 D, E and F), with special 
attention to the Figures 5 and 7 D, the one with the most intense loss in size and G1 arrest. 
Taking in consideration all the results obtained in these experiments an optimal cell density 400 
000 cells per mL was used in all further experiments. 
 
2.2 A chemical epistasis size screen with rapamycin  
 
The possibility to interrogate gene function in a large-scale manner also brings different 
possibilities to be added to the interrogation about epistasis. In particular, chemical perturbations 
can mimic genetic mutations such that the addition of specific drugs can be used as a powerful 
means to investigate gene interactions and functions, regulation and dynamics of essential genes 
and drug mechanism of action. Epistasis or genetic interaction was first discussed by Bateson 
(1909), as the ‘masking of one mutation by another'. Nevertheless, the meaning of the word 
developed into many interpretations. Currently ‘epistasis’ is understood as different events that 
regulate molecular mechanisms controlling biological outcomes and phenotypes. Also, the term 
can be used as ‘intramolecular’ and ‘intermolecular epistasis’, interactions that can occur 
between gene variants and between different genes; ‘antagonistic’ or ‘synergistic epistasis’, 
alleviating or amplifying interactions that can be between a drug and one or more gene function 
(Lehner, 2011). Therefore, the use of drugs to investigate genetic interactions can be defined as 
chemical epistasis. 
 
Accordingly, the aim was to interrogate the genetic network of cell size control in human cells 
by using a chemical epistasis approach in conjunction with whole-genome CRISPR/Cas9 loss-






















Figure 8: EKO library cell fractions by cell volume. 
The extended knockout library was treated with rapamycin and fractionated based on cell 
volume by counterflow centrifugal elutriation. Cell fraction distributions show the appropriate 
achievement of defined fractions with different sizes. 
 
A CRISPR-based whole-genome knockout library (EKO library) pool was treated with the 
specific mTOR inhibitor rapamycin at 10 nM for 24 hours and further allowed to grow for 7 
(Figure 8 A) and 14 days (Figure 8 B). Different library growth times referred to as short term 
and long term were generated to compare the impact of in two different times the impact of 
protein depletion. Considering that some proteins may have a longer half-life therefore, residual 
levels might be influencing genetic interactions. After rapamycin treatment the libraries were 
Elutriation long term B) 




fractionated using counterflow elutriation. This method separates cells from different sizes using 
the opposition of centrifugal force - produced by the separation chamber coupled in a spinning 
rotor - with the fluidic force imposed by the constant of a fluid. The fluid force created by the 
fluid pump is increased gradually, allowing the displacement of different cell fractions (Figure 




Figure 9: Cell size fractionation based on size using counterflow elutriation 
Schematic representation of counterflow elutriation functioning. (a) Separation chamber coupled 
to the rotor in a centrifuge. Media (low density fluid) containing the cells are pumped to the 
separation chamber. (b) After the cells are loaded in the chamber bigger cells stay at the bottom 
of the chamber whereas smaller cells stays at the top, based on the opposition between fluidic 
force and centrifugal force. (c) In our experiment the density of the liquid was not changed. 
Instead, the fluidic force was gradually increased using a peristaltic pump chamber. Therefore, 
fluidic force pushed cells out of the chamber allowing the obtaining of different cell size 
fractions. Taken from Morijiri et al. (2010). 
 
Fractions from different sizes were successfully generated (Figure 8 A and B). A slight 
difference can be observed between the two libraries when comparing the percentage of cells in 
the smaller fractions. This suggests that the rapamycin treatment drives the population to a 
smaller size as expected. 
 
After obtaining cell fractions separated by size, the genomic DNA isolated from each one of the 
different fractions were used to recover the integrated sgRNA sequences (Figure 10). All the 
samples obtained yielded good amplification quality, and the respective negative controls were 










Figure 10: Elutriation samples labeling PCR 1. 
Expression of specific band obtained from the recovery of sgRNAs by PCR amplification. Each 
band corresponds to a different cell size fraction. Red stars correspond to negative controls and 
yellow starts are not used lines. 
 
After the recovery of the sgRNAs it was necessary to reduce the genomic DNA ratio, 
reamplifying the sgRNAs, insert the barcodes responsible for identifying the sequences to each 





Figure 11: Elutriation samples labeling PCR 2. 
Gels showing the amplification of specific bands for the reamplification of sgRNAs from 
different cell size fractions. Each band corresponds to a different cell size fraction, red stars 
corresponding to negative controls and yellow starts are not used lines. 
 
After preparation samples were sent to sequencing and analyzed using the RANKS algorithm 
(Bertomeu et al., 2017). This statistical analysis allows the calculation of the level of depletion of 
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each sgRNA in pooled CRISPR/Cas9 library screen. The algorithm establishes a rank of genes 
that most likely are able to affect cell size upon its knockout. The barcode primers used to label 
the various cell sizes enables the quantification of gene enrichment in specific cell size fractions. 
 
2.3.  Analysis of the rapamycin size screen dataset 
 
Elutriation screens in the presence of rapamycin were compared with a previous EKO library 
elutriation screen in the absence of rapamycin, which was performed by others in the Tyers 
laboratory. A noticeable difference was evident in the range of hit values between the untreated 
versus the short-term (Figure 12) and long-term (Figure 13) rapamycin treatments, and the 
combined screens (Figure 14). In the short-term versus non-rapamycin the scale ranges from -4 
to 4 (i.e., depletion and enrichment respectively), while comparison with the long-term and the 
combined rapamycin score the hits range from scores of to -6 to 6. 
 
  
Figure 12: Comparison between short-term rapamycin-treated versus untreated EKO 
library size screens. 
RANKS analysis comparing the level of gene depletion in both short-term treatment versus not 




This initial result indicates that the genetic drift is driven by a longer time after the rapamycin 
treatment might be leading to the depletion of any residual levels of essential gene products, 
therefore enriching the populations that carry knockouts that impact cell size, and potentially 
increasing screen sensitivity. Only the strongest hits from the screens will be discussed, i.e., 
those genes that upon knockout generated a pronounced difference in the phenotype in 













Figure 13: Comparison between long-term rapamycin-treated versus untreated EKO 
library size screens. 
Analysis comparing the level of gene depletion in both long-term treatment versus not treated. 







Figure 14: Comparison between combined short-term and long-term rapamycin-treated 
versus untreated EKO library size screens. 
Analysis comparing the level of gene depletion in both long-term and short-term treatment 
versus not treated. The dot plot shows genes that upon its knockout, presents a different cell size 
phenotype.  
 
A complex network of hits that activate or suppress mTORC1 signaling is revealed by the 
screens. With respect to activators, the TSC complex, Rag GTPases, Rheb, and other factors 
involved in the activation of mTORC1 will be discussed. 
 
In the results, the TSC1, TSC2, RRAGA and MAT2A knockouts, all generated a smaller 
phenotype in the rapamycin treatment in comparison with no treatment. The TSC proteins form a 
tumor suppressor complex that mediates the regulation of mTOR by growth factors and energy 
levels (Sancak et al., 2010; Lee et al., 2009; Kim & Kim, 2016). The TSC1 and TSC2 genes 
serve as validation of the screen strategy since these genes were expected to influence cell size in 
a mTOR-dependent manner. TSC1/2 function upstream mTOR, forming a heterodimer that 
negatively regulates mTOR activity (Lam, Siroky, & Henske, 2018; Wullschleger et al., 2006a), 
as orchestrated by energy and growth factors levels (Laplante & Sabatini, 2012). The knockout 
of both TSC1 and TSC2 produced a phenotype of smaller cells in the rapamycin treatment in 
comparison with the no rapamycin treatment. As an upstream inhibitor of mTOR, the loss of 
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those genes function would lead to uncontrolled activation of mTOR, leading to a bigger 
phenotype as found in the screen without rapamycin where TSC2 as the 2nd top and TSC1 was 
the 15th top hit to generate a large size phenotype (data not shown). The opposite phenotype 
obtained upon the loss of TSC1 and TSC2 in the presence of rapamycin, i.e., a much smaller size 
than in the untreated control screen illustrates chemical epistasis. That is, the drug masks the 
effect of gene loss by mimicking a genetic interaction where different molecules antagonize the 
TSC complex action as discussed by Bateson (1909), Lehner (2011) and many others. 
 
RRAGA is the gene encoding the Ras-related GTP-binding protein A. RRAGA forms a complex 
that mediates the activation of mTOR by Rheb in the presence of amino acids depending on its 
activation by GATOR1, a GAP protein (GTPase activating protein) for RagA/B (Gu et al., 
2017). Rag GTPases are the specific regulators of amino acid levels in the mTOR pathway (Kim 
et al., 2008). The Rag proteins RagA, RagB, RagC, and RagD form heterodimers that in the 
presence of GTP-bound RagB, interacts with TORC1 and activates it (Sancak et al., 2010). As 
previously shown, Rag proteins reside in the surface of lysosomes, where the ragulator complex 
(MAPKSP1, ROBLD3, and c11orf59), interacts with the Rag GTPases. This interaction is 
essential to mTOR lysosomal localization, and pathway activation showing that the Ragulator-
Rag complex is essential to mTOR activation (Sancak et al., 2010). Therefore, the knockout of 
one of those proteins would disrupt mTOR’s activation system and expectedly give rise to a 
small phenotype. 
 
Interestingly, RRAGA was the only RAG protein that had a strong differential effect on size 
since in the absence of rapamycin none of the RAG genes scored as a strong hit. Kim et al. 
(2008), found that in Drosophila melanogaster that within the dimers RagA and RagB is 
dominant in TORC1 regulation, which may help explain why RRAGA scored stronger than the 
other Rags. These authors proposed a model whereby Rag acts in a parallel in a pathway parallel 
to the TSC–Rheb axis in TORC1 activation. Therefore, in the absence of rapamycin cells might 
be generating a resistance mechanism by the inhibition of the TSC complex, and in the presence 
of rapamycin this bypass does not work because rapamycin works downstream the TSC 
complex. This may perhaps explain why in the presence of rapamycin RRAGA scored as a 




In the context of upstream mTOR activation by amino acids, the RAG complexes are activated 
by the GATOR1 complex. In contrast to arginine and leucine, the amino acid methionine is 
sensed indirectly by a complex involving SAM and SAMTOR. In previous findings, loss of 
MAT2A (a methionine adenosyltransferase), prevents mTOR sensing of methionine by the 
blockage of its conversion to SAM, therefore inhibiting mTOR activation (Gu et al., 2017). The 
knockout of MAT2A scored as one of the top 15 genes that generated a small phenotype in my 
screens in the presence of rapamycin. In the screen without rapamycin MAT2A was not an 
important regulator of size as its loss caused only a slight decrease in size. Therefore, in the 
presence of rapamycin the methionine-dependent signal may be required to maintain a minimal 
level of mTOR activation and thereby affect cell size. 
 
FKBP1A, also known as FKBP12, is a direct co-factor for rapamycin dependent inhibition of 
mTOR and as such is expected give rise to a strong size phenotype only in the presence of 
rapamycin. This prediction was fulfilled since the FKBP1A knockout causes a large cell size 
phenotype in the presence of rapamycin. FKBP12  is best characterized for its role as an 
interactor of rapamycin, and another inhibitor called FK506 (an important immunosuppressant 
used to reduce organ rejection) that inactivates calcineurin signaling (Hausch et al., 2013) (Choi 
et al., 1996). Consistent with this specificity, knockout of calcineurin did not modify cell size in 
either the rapamycin treated or untreated size screens. In summary, genes known to be required 
for either activation or inhibition of mTOR resulted in differential size phenotypes in the 
presence of rapamycin. 
 
Many other KOs downstream mTOR scored within the top 15 genes that led to a large size 
phenotype and the top 15 that led to a small size phenotype. mTOR regulates a plethora of cell 
responses to environmental cues in part through its known effector substrates, S6Ks and 4EBPs 
(Wang & Proud, 2011). Even though those direct mTOR effectors were not recovered in the 
screens, some components of the EIF3 family scored as size regulators. Some of the EIF3 family 
components were found to function scaffolding the association between pre-initiation complexes, 




The EIF3 eukaryotic initiation factor coordinates many steps of translation initiation and 
ribosome interactions, and is considered the most complex of the eIFs (Valášek et al., 2017). 
Composed of 13 EIF3 subunits, previous studies have found that EIF3 functions as either an 
activator or repressor of cap-dependent translation with a central role in the 40S initiation 
complex (Lee, Kranzusch, & Cate, 2015; Miyamoto, Patel, & Hershey, 2005). Of particular note, 
Miyamoto et al. (2005) found that rapamycin inhibits EIF3 association with the ribosome, as 
well as EIF3 complex formation. Three subunits of the EIF3 were found to give a rapamycin 
sensitive size phenotype: EIF3A and EIF3H scored in the short-term screen, whereas EIF3B 
scored in the long term-screen. In the combined screen scores only EIF3A proved to be one of 
the top hits. Of these subunits, the EIF3B knockout caused a bigger phenotype upon the 
rapamycin treatment, whereas EIF3A and EIF3H knockout caused smaller phenotypes in the 
short-term rapamycin treatment, when compared with no rapamycin. From the genetic screen 
data alone it is not possible to infer the exact relationship between mTOR inhibition and EIF3 
subunit function, but this is likely to be complex given the known activating and inhibitory roles 
of EIF3 in translation. 
 
Ribosome biogenesis is strongly implicated as a target of mTOR cell size regulation, and this 
complex process responds to wide range of cellular stresses (Yang, Yang, & Yi, 2018). Among 
differential size hits in my screens, NOL6 encodes the protein Nrap which is conserved from 
yeast to humans and interacts with pre-rRNA primary transcripts (Yang et al., 2018). RPL10 
encodes the ribosomal protein L10 which participates in late steps of ribosomal 60S assembly 
and appears to also affect the expression of oxidative stress and ROS generation proteins (Yang 
et al., 2018). Both of these genes caused a small cell size upon rapamycin treatment. 
 
Calcium homeostasis is critical for cancer suppression and disruption of this process is one of the 
hallmarks of cancer (Hanahan & Weinberg, 2000). Proper mitochondrial function is also crucial 
for cell viability through production of ATP by oxidative phosphorylation, intracellular Ca
++
 
homeostasis and the regulation of apoptosis/autophagy, among other processes (Huang et al., 
2017; Arroyo et al., 2016). In this context, knockout of many genes involved in mitochondrial 
function gave rise to size phenotypes. I found that the calcium transporters ATP2A2 and 
ATP2B1 caused larger and smaller size phenotypes respectively. Other genes that are involved in 
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mitochondrial function included OPA1 and WBSCR16, knockout of which generated a large cell 
size phenotype upon rapamycin treatment. Huang et al. (2017) provided evidence for 
WBSCR16-OPA1 physical interaction as being important for mitochondrial function. In 
addition, functional module regulating mitochondrial rRNA and intra-mitochondrial translation 
contains WBSCR16 (Arroyo et al., 2016). 
 
Yoon et al. (2017) found a link between mTORC1 signaling and the regulation of autophagy in 
neurons is mediated by mitochondrial functions. The mitochondrial proteins OGDH and NRD1 
regulate production of the TCA cycle intermediate α-ketoglutarate, and their loss promotes 
mTORC1 activation and autophagy impairment. Conversely, rapamycin alleviates those 
responses by reducing the functions of these proteins, mTORC1 activation and autophagy. In my 
screens, loss of these two genes that interact with NRD1, DNAJA3 and LONP1, which are a 
mitochondrial co-chaperone and a chaperone respectively (Yoon et al., 2017), caused a larger 
cell size upon rapamycin treatment. 
 
Finally, a number of other size screen hits appeared to have cell type-specific functions including 
IKZF2, NKTR, SH3GL1 and CSK, all of which are involved in lymphocyte development, 
signaling or function (Chan, 2019; Ma et al., 2007; Vang et al., 2001). These hits may reflect the 
intersection between mTOR signaling and developmental control of cell size. 
 
In summary, my genome-wide CRISPR/Cas9 knockout genetic screens have revealed the broad 
role of mTOR in size control through chemical epistasis with rapamycin. These results provide 
new insights into the pathways that control cell size. Below the general ramification of these 





This study documented the effects of cell density on the interface between proliferation, cell 
cycle and cell size. Then the genes were  systematically surveyed that regulate cell size in an 
mTOR-dependent fashion by using a whole-genome knockout screening approach in the 
presence or absence of rapamycin, a specific mTOR inhibitor. Since mTOR is directly inhibited 
by rapamycin, mTOR regulators and effectors are expected to be differential hits in these size 
screens. 
 
Of the mTOR upstream regulators the most well-studied are the TSC complex, Rag GTPases and 
Rheb. Here, both of the regulators, or partner proteins, were identified as mTOR dependent size 
genes. Knockout of the TSC complex led to reduced cell size in the presence of rapamycin, 
compared to the pronounced large size phenotype in the absence of rapamycin. As discussed 
above the TSC complex is an important mTOR negative regulator, and these results strongly 
validate the differential size screen strategy based on the concept of chemical epistasis (Dibble 
and Cantley 2015). In contrast, RAGGA and MAT2A knockouts displayed smaller phenotypes 
in the presence of rapamycin when compared to the same knockouts in the absence of 
rapamycin. Interestingly, the loss RAGGA and MAT2A itself have already caused both of those 
clones to be reduced in cell size – loss of MAT2A showed a slight size loss, while the loss of 
RRAGA had a more expressive size loss - but the presence of rapamycin in both cases enhanced 
the small phenotype. Both MAT2A and RAGGA are dependent on GATOR1 activation, and are 
important amino acid sensors (Gu et al., 2017). 
 
FKBP1A is the direct target of rapamycin and FK506 (Choi et al. 1996). Both drugs are direct 
mTOR inhibitors by their ability to bind to FKBP1A hydrophobic binding pockets, therefore 
being able to exert its immunosuppressive properties by the inhibition of ternary complexes 
between FKBP1A and mTOR (Hausch et al., 2013). As previously discussed, 
PI3K/AKT/mTORC1 pathway is crucial regulator of cell growth and size, highly conserved from 
yeast to mammals, therefore our result showing the loss of size in FKBP1A (Gonzalez & Rallis, 




Among the knockouts downstream mTOR leading to size phenotypes, the EIF3 subunits EIF3A, 
EIF3B, and EIF3H were hits, amongst which EIF3B gave rise to bigger cells and EIF3A and 
EIF3H to smaller cells. As discussed above, the EIF3s have a tight correlation with translational 
mechanisms and interact with ribosome biogenesis factors (Sha et al., 2009; Wild et al., 2010). A 
previous study found that the depletion of EIF3B or EIF3C, or both proteins, decreases cell size. 
The same study  discussed that EIF3B or EIF3C have a role in cell size control apart from 
regulating translational initiation, since the restoration of those proteins recovered cell size 
effects and those effects apparently have no correlation with S6K1-signaling (Schipany et al., 
2015). In the present study we found that the eIF3B knockout had a slight smaller phenotype, 
while the same knockout in the presence of rapamycin had a bigger phenotype. Further impacts 
of EIF3A and EIF3H in cell size were not found. 
 
Excitingly, many other hits scored as size regulators uncovered the importance of translation 
initiation factors (as already discussed), mitochondrial function and ribosome biogenesis. 
Between the mitochondrial function related proteins, WBSCR16 and OPA1 knockouts led to a 
bigger phenoype upon rapamycin treatment. As discussed before, Huang et al. (2017) found 
evidence of a physical interaction between WBSCR16-OPA1 as being important for 
mitochondria fusion and therefore function and that its loss caused an inhibition in cell growth, 
increase in apoptosis and blockage at the G1-S interface. Similar results were found previously 
for OPA1(Cipolat et al., 2004). Therefore, an interesting question would be if WBSCR16-OPA1 
is really physically interacting. This would definitely contribute to the chronic neurodegenerative 
conditions field. 
 
Last, in the ribosomal biogenesis context, RPL10 and NOL6 knockouts led to cell size 
perturbation. RPL10 is commonly known to participate in the late steps of 60s ribosome 
assembly (Dowdy et al., 1991), but more recently investigated for its extra ribosomal roles. Yang 
et al. (2018) found RPL10 in the mitochondria regulating ROS (reactive oxygen species) in 
pancreatic cancer, and while in this specific study cell size was not observed, many other studies 
drew a parallel between RPL10 and other cancer features. While in epithelial ovarian cancer 
overexpression of RPL10 was related to higher levels of cell viability, migration and invasion, at 
lower expression levels the same features were decreased (Shi et al., 2018). In prostate cancer 
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RPL10 levels were decreased in its developmental stages and its higher levels were correlated to 
tumor deterioration at late stages (Altinok et al., 2006). NOL6 is the gene that codifies the 
protein NRAP. This protein was isolated and characterized recently, and it correlates to ribosome 
biogenesis by the association with the pre-rRNA transcript (Utama et al., 2002). In humans a 
homozygous mutation predicted to introduce a stop codon was found in patients with dilated 
cardiomyopathy. In mice the overexpression of NRAP caused right ventricular dysfunction 
(Truszkowska et al., 2017; Lu et al., 2011). 
 
Overall, my genetic screen data compared genome-wide size screen hits in the presence and 
absence of rapamycin. This study highligted many candidate genes, as well as processes that 
disrupted cell size in the presence of the speficic mTOR inhibitor rapamycin. Here the most 
prohiminent cases were discussed, since it would be impossible to discuss case by case. Those 
results found in this study were also validated by the identification of direct regulators of mTOR 
(i.e., FKBP1 and components of the TSC complex), those candidates which were already 
expected to score, are well known for their previous characterization, and were clearly related to 
mTOR. On the other hand, many other candidates did not have much previous characterizaztion 
and/or described correlation with with mTOR (i.e., WBSCR16, OPA1, RPL10, NOL6), which 
made it challenging to draw a line between the results found and its relashionship. Nevertheless, 
even in the cases where there was not a clear correlation with the mTOR pathway, an association 
with cell cycle control, cell size and diseases involving changes in size were found. Those results 
suggest that the cell size regulation is intimately correlated to many conditions, and it opens 
questions that remain to be answered in different fields. 
 
In context of this specific sutdy, I would investigate upstream and downstream mTOR points that 
are more related to direct regulation and responses to this pathway, using further functional 
studies as future perspectives: As discussed above, Kim et al. (2008) proposed a model whereby 
Rag acts in a parallel to the TSC–Rheb axis in TORC1 activation. In this context, it would be 
important to validate these results and investigate the possible interactions between the TSC–
Rheb and RAGGA-MATA2 pathways. In my results TSC1, TSC2, RRAGA and MAT2A 
knockouts, generated a smaller phenotype in the rapamycin treatment in comparison with no 
treatment. For this reason, the generation of cell lines knockouts for TSC1, TSC2, RRAGA and 
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MAT2A, in the presence and absence of rapamycin, followed by western blots anti phospho-
mTOR, GATOR1 and phospho-TCS1/TSC2. This experiment would provide further mechanistic 
insights about the possible interactions between the TSC–Rheb and RAGGA-MATA2 pathways. 
Notably, ribosome biogenesis has previously been shown to be a major target of mTOR in yeast 
and mammalian cells (Jorgensen et al., 2004; Jorgensen et al., 2002; Jorgensen & Tyers, 2004; 
Chaillou, Kirby, & Mccarthy, 2014). In this context, I would investigate the eIF3 family using a 
similar approach that was taken: Since the three subunits EIF3A, EIF3H and EIF3B had a 
rapamycin sensitive size phenotype, first two smaller and EIF3B bigger phenotype, the 
generation of knockout lines for these genes in the presence and absence of rapamycin followed 
by cell size validation assessment. Further, western blots anti the three subunits would be 
performed in both presence and absence of rapamycin. As next steps, I would do the analysis of 
the changes in the translatome using affinity purification of ribosomes, that would allow me to 
follow the changes in the ribosomal proteins and their modifications (Halbeisen, Scherrer, & 
Gerber, 2009).  
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Materials and methods 
 
Cell culture and size analysis 
 
Cells were kept in culture at 37°C and 5% CO2. Nalm-6 cells were a kind gift from Dr. Stephen 
Elledge (Harvard Medical School) and 293T cells (CRL-3216) were obtained from ATCC. 
Nalm-6 were grown in RPMI medium supplemented with 10% Fetal Bovine Serum (FBS), 
Sigma (catalog number F1051; lot 18D001) and 293T cells were grown in DMEM medium 
supplemented with 10% FBS, Wisent (catalog number 098150; lot 185705). 
 
Cells measured using Z2 Coulter counter (Beckman Coulter), which sizes and counts particles 
based on changes in the electrical impedance produced by the cells suspended in the carrier 
liquid with known electrolyte concentration. Cells in suspension are pushed through the aperture, 
with a known size in a specific and reproducible volume allowing the coulter to measure the 
voltage pulse, giving a precise particle number and volume.  
 
Cell size screens 
 
The EKO library, as previously generated (Bertomeu et al., 2017), was transduced in its 
uninduced version in a low multiplicity of infection (MOI) of 0.5. For the screen 8 aliquots 
containing 22.5 million cells aiming for mortality rates of around 20% and obtain a final number 
of 140 million cells. After thawing, the cells were counted every day using Z2 Coulter counter 
(Beckman Coulter), until normal doubling time (24 hours) was achieved, typically after 2 days. 
For all additional steps cultures were diluted daily to 400,000 cells per ml to maintain 
asynchronous exponential proliferation, and kept at a final total number of 100 million cells for 7 
days. To induce Cas9 cells were cultured in the presence of doxycycline at 2 µg per ml for 7 
days, followed by culture for 7 days with fresh media without doxycycline. After knockout 
induction, cells were treated for 24 hours with rapamycin (10nM) for the short-term elutriation 
and, for the long-term elutriation the same rapamycin treatment was carried out for 13 days. 
Cells obtained from both short- and long-term rapamycin were fractionated by centrifugal 
elutriation. For each treatment a total of 800 million cells were centrifuged (4°C at 400 g), 
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resuspended in 50 mL of media with 1% FBS to slow proliferation, and loaded in the 
centrifugation chamber (Beckman Coulter Avanti J-26 XPI centrifuge fitted with the JE-5.0 
elutriation system using the small 4 ml chamber) using a peristaltic pump (Masterflex L/S Cole-
Parmer). As a control 2 samples of 40 million cells were obtained and frozen prior elutriation. 
For each fraction,= 200 mL of cells were collected in 1% FBS by increasing the flow 
centrifugation rate. A total of 8 fractions were obtained, and for each fraction 1 mL of cells were 
collected to measure the cell size at the Z2 Coulter counter (Beckman Coulter). Then, each 
fraction was centrifuged (2000g, 4°C, 15 minutes), washed with 10mL of cold PBS  1X, re-
centrifuged and storage at -20°C until DNA extraction. DNA from each fraction were separately 
extracted using QIAmp DNA blood maxi and mini kits (Qiagen) according to manufacturer’s 
protocol. The frozen cell pellet was homogenized in 1mL of Trizol, genetic material was 
quantified, and purity assessed by 260/280 and 260/230 ratios. sgRNA sequences were amplified 
by two rounds of PCR as previously described (Bertomeu et al. 2017), and the libraries were 
pooled in equimolar concentration. The sgRNA primers were configured for 50 base pair single 





Analysis was performed using RANKS, an in-house constructed algorithm for all RefSeq genes 
in the EKO library (Bertomeu et al., 2017). Gene knockouts that were enriched or depleted in 
both smallest and biggest fractions were first determined. Gene knockouts ranked as disrupting 
cell size, were determined by the comparison of the sgRNA frequencies from the combination of 
the smallest fractions versus the largest fractions. Short and long-term rapamycin treatment were 
compared to a previous elutriation screen performed in the Tyers lab without rapamycin (T. 
Bertomeu, unpublished), to generate a list of genes that specifically yielded smaller and larger 
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